Share This Author
American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection
Whether to test for H. pylori in patients with functional dyspepsia, gastroesophageal reflux disease (GERD), patients taking nonsteroidal antiinflammatory drugs, with iron deficiency anemia, or who are at greater risk of developing gastric cancer remains controversial.
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection
- W. Chey, G. Leontiadis, C. Howden, S. Moss
- Medicine, BiologyThe American Journal of Gastroenterology
- 1 February 2017
Most patients will be better served by first-line treatment with bismuth quadruple therapy or concomitant therapy consisting of a PPI, clarithromycin, amoxicillin, and metronidazole.
Rifaximin therapy for patients with irritable bowel syndrome without constipation.
Among patients who had IBS without constipation, treatment with rifaximin for 2 weeks provided significant relief of IBS symptoms, bloating, abdominal pain, and loose or watery stools.
Naloxegol for opioid-induced constipation in patients with noncancer pain.
- W. Chey, L. Webster, M. Sostek, J. Lappalainen, P. Barker, J. Tack
- MedicineThe New England journal of medicine
- 18 June 2014
Treating naloxegol, an oral, peripherally acting, μ-opioid receptor antagonist, for the treatment of opioid-induced constipation resulted in a significantly higher rate of treatment response, without reducing opioid-mediated analgesia.
An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
This monograph was developed to educate physicians about its epidemiology, diagnostic approach, and treatments of Irritable Bowel Syndrome to critically evaluate the rapidly expanding research about IBS.
Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety
Linaclotide 290 μg once daily significantly improved abdominal and bowel symptoms associated with IBS-C over 26 weeks of treatment, and Statistically significant differences from placebo were observed for responder and continuous end points over 26 Weeks of treatment.
Clinical trial: lubiprostone in patients with constipation‐associated irritable bowel syndrome – results of two randomized, placebo‐controlled studies
This clinical trial aimed at determining the causative mechanism behind irritable bowel syndrome with constipation (IBS‐C) and its prognosis was successful in patients with symptomatic IBS-C.
Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation.
A Meta-Analysis of the Utility of C-Reactive Protein, Erythrocyte Sedimentation Rate, Fecal Calprotectin, and Fecal Lactoferrin to Exclude Inflammatory Bowel Disease in Adults With IBS
- S. Menees, Corey Powell, J. Kurlander, A. Goel, W. Chey
- MedicineThe American Journal of Gastroenterology
- 1 March 2015
A systematic review and meta-analysis to evaluate the utility of C-reactive protein (CRP), erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to distinguish between patients with IBS and inflammatory bowel disease (IBD) and healthy controls (HCs).
Can endoscopic ultrasound or magnetic resonance cholangiopancreatography replace ERCP in patients with suspected biliary disease? A prospective trial and cost analysis
EUS was most useful for confirming a normal biliary tree and should be considered a low-risk alternative to ERCP, and although MRCP had the lowest procedural reimbursement, the initial EUS strategy had the greatest cost-utility by avoiding unnecessary E RCP examinations.